• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测变异株改良 COVID-19 疫苗加强针的效力。

Predicting the efficacy of variant-modified COVID-19 vaccine boosters.

机构信息

Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.

WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

出版信息

Nat Med. 2023 Mar;29(3):574-578. doi: 10.1038/s41591-023-02228-4. Epub 2023 Mar 2.

DOI:10.1038/s41591-023-02228-4
PMID:36864253
Abstract

Booster vaccination for the prevention of Coronavirus Disease 2019 (COVID-19) is required to overcome loss of protection due to waning immunity and the spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Studies have assessed the ability of existing ancestral-based vaccines as well as novel variant-modified vaccine regimens to boost immunity to different variants, and a crucial question is to assess the relative benefits of these different approaches. Here we aggregate data on neutralization titers from 14 reports (three published papers, eight preprints, two press releases and notes of one advisory committee meeting) comparing booster vaccination with the current ancestral-based vaccines or variant-modified vaccines. Using these data, we compare the immunogenicity of different vaccination regimens and predict the relative protection of booster vaccines under different scenarios. We predict that boosting with ancestral vaccines can markedly enhance protection against both symptomatic and severe disease from SARS-CoV-2 variant viruses, although variant-modified vaccines may provide additional protection, even if not matched to the circulating variants. This work provides an evidence-based framework to inform choices on future SARS-CoV-2 vaccine regimens.

摘要

加强针接种对于预防 2019 年冠状病毒病(COVID-19)是必要的,因为它可以克服由于免疫减弱和新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)变异株传播而导致的保护力下降。研究已经评估了现有基于原始株的疫苗以及新型变异株修饰疫苗方案增强对不同变异株免疫力的能力,一个关键问题是评估这些不同方法的相对益处。在这里,我们汇总了来自 14 份报告(三篇已发表的论文、八篇预印本、两份新闻稿和一次顾问委员会会议的说明)的中和滴度数据,这些报告比较了加强针接种与当前基于原始株的疫苗或变异株修饰疫苗的效果。利用这些数据,我们比较了不同接种方案的免疫原性,并预测了在不同情况下加强针疫苗的相对保护作用。我们预测,用原始疫苗进行加强接种可以显著增强对 SARS-CoV-2 变异病毒引起的有症状和严重疾病的保护作用,尽管变异株修饰疫苗即使与流行变异株不匹配,也可能提供额外的保护。这项工作为未来 SARS-CoV-2 疫苗方案的选择提供了一个基于证据的框架。

相似文献

1
Predicting the efficacy of variant-modified COVID-19 vaccine boosters.预测变异株改良 COVID-19 疫苗加强针的效力。
Nat Med. 2023 Mar;29(3):574-578. doi: 10.1038/s41591-023-02228-4. Epub 2023 Mar 2.
2
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
3
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
4
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
5
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.变异的 SARS-CoV-2 mRNA 疫苗在小鼠中作为初级或加强系列疫苗具有广泛的中和作用。
Vaccine. 2021 Dec 17;39(51):7394-7400. doi: 10.1016/j.vaccine.2021.11.001. Epub 2021 Nov 8.
6
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.同源加强接种 SARS-CoV-2 重组刺突蛋白疫苗(NVX-CoV2373)的安全性和免疫原性:一项随机、安慰剂对照、2 期临床试验的二次分析。
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
7
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.复制 RNA 平台使我们能够快速应对 SARS-CoV-2 奥密克戎变异株,与原始疫苗相比,该平台在未经免疫的仓鼠中引发更强的保护作用。
EBioMedicine. 2022 Sep;83:104196. doi: 10.1016/j.ebiom.2022.104196. Epub 2022 Aug 4.
8
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.在健康成年人中,SARS-CoV-2 变异 mRNA 疫苗加强针的安全性和免疫原性:一项中期分析。
Nat Med. 2021 Nov;27(11):2025-2031. doi: 10.1038/s41591-021-01527-y. Epub 2021 Sep 15.
9
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛,2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
10
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.通过临床终点预测疫苗诱导的中和抗体的长期动力学和针对 SARS-CoV-2 Delta 变异株的时变疫苗特异性疗效。
BMC Med. 2022 Jan 28;20(1):36. doi: 10.1186/s12916-022-02249-9.

引用本文的文献

1
Improving the evidence base for COVID-19 vaccines.提高新冠病毒疫苗的证据基础。
Nat Med. 2025 Sep 4. doi: 10.1038/s41591-025-03908-z.
2
Bivalent mRNA booster encoding virus-like particles elicits potent polyclass RBD antibodies in pre-vaccinated mice.编码病毒样颗粒的二价mRNA加强针在预先接种疫苗的小鼠中引发强效多类RBD抗体。
bioRxiv. 2025 Aug 19:2025.08.18.670983. doi: 10.1101/2025.08.18.670983.
3
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.免疫接种的多样性对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体功能替代指标有强烈影响。

本文引用的文献

1
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.ENSEMBLE 单剂量 Ad26.COV2.S 疫苗效力临床试验的免疫相关性分析。
Nat Microbiol. 2022 Dec;7(12):1996-2010. doi: 10.1038/s41564-022-01262-1. Epub 2022 Nov 10.
2
Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.β佐剂重组加强疫苗的免疫原性和安全性。
N Engl J Med. 2022 Jul 28;387(4):374-376. doi: 10.1056/NEJMc2206711. Epub 2022 Jun 29.
3
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
NPJ Vaccines. 2025 Jul 29;10(1):175. doi: 10.1038/s41541-025-01226-6.
4
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.单价奥密克戎KP.2适应性BNT162b2新冠疫苗在成人中的安全性和免疫原性:一项2/3期试验的单臂子研究
Infect Dis Ther. 2025 Jul 1. doi: 10.1007/s40121-025-01185-4.
5
Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.肺部协调的早期免疫反应是有效控制SARS-CoV-2复制所必需的。
Nat Commun. 2025 Jun 25;16(1):5390. doi: 10.1038/s41467-025-60885-0.
6
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults.2023 - 2024年成人新冠病毒疫苗有效性评估
JAMA Netw Open. 2025 Jun 2;8(6):e2517402. doi: 10.1001/jamanetworkopen.2025.17402.
7
Evaluating the impact of COVID-19 vaccination strategies on infections and hospitalisations in Victoria with non-seasonal epidemic wave patterns: a modelling study.评估新冠病毒疫苗接种策略对维多利亚州非季节性疫情波模式下感染和住院情况的影响:一项建模研究。
Med J Aust. 2025 Jun 16;222(11):558-566. doi: 10.5694/mja2.52677. Epub 2025 Jun 1.
8
Predicting pathogen evolution and immune evasion in the age of artificial intelligence.在人工智能时代预测病原体进化与免疫逃逸
Comput Struct Biotechnol J. 2025 Mar 28;27:1370-1382. doi: 10.1016/j.csbj.2025.03.044. eCollection 2025.
9
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)结合疫苗可引发强大的免疫反应,能够抵御不断演变的病毒变体。
Vaccine. 2025 Apr 30;54:126988. doi: 10.1016/j.vaccine.2025.126988. Epub 2025 Mar 6.
10
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.被动输注一种S2茎区广泛中和抗体可保护恒河猴免受SARS-CoV-2感染并减轻下呼吸道炎症。
PLoS Pathog. 2025 Jan 23;21(1):e1012456. doi: 10.1371/journal.ppat.1012456. eCollection 2025 Jan.
解析 COVID-19 中 T 细胞反应的相对重要性:主角还是配角?
Nat Rev Immunol. 2022 Jun;22(6):387-397. doi: 10.1038/s41577-022-00716-1. Epub 2022 Apr 28.
4
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial.CVnCoV( CureVac )试验中体外中和水平与保护的相关性。
Clin Infect Dis. 2022 Aug 24;75(1):e878-e879. doi: 10.1093/cid/ciac075.
5
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.mRNA-1273加强疫苗接种后对SARS-CoV-2奥密克戎变体的中和作用。
N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.
6
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.mRNA-1273 新冠疫苗有效性临床试验的免疫相关性分析。
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
7
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.中和抗体滴度作为预测对 SARS-CoV-2 变异体的保护作用以及加强免疫的影响的指标:一项荟萃分析。
Lancet Microbe. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6. Epub 2021 Nov 15.
8
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.mRNA 疫苗可诱导对 SARS-CoV-2 及其关注变种的持久免疫记忆。
Science. 2021 Dec 3;374(6572):abm0829. doi: 10.1126/science.abm0829.
9
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
10
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.在健康成年人中,SARS-CoV-2 变异 mRNA 疫苗加强针的安全性和免疫原性:一项中期分析。
Nat Med. 2021 Nov;27(11):2025-2031. doi: 10.1038/s41591-021-01527-y. Epub 2021 Sep 15.